Analysis Tools
mortality/aging
|
• mutants die about 2 months after tamoxifen treatment
|
cardiovascular system
|
• after tamoxifen treatment enlarged hyperchromatic myocyte nuclei are seen
• after tamoxifen treatment intercalated disc structures and intercellular space are absent
• after tamoxifen treatment sarcomeres appear distorted and compressed with wider, less dense Z-lines
|
|
• after tamoxifen treatment intercalated disc structures are absent
|
|
• modest dilation of the atria after tamoxifen treatment
|
|
• after tamoxifen treatment hearts appear elongated and flacid
|
|
• modest dilation of the ventricles after tamoxifen treatment
|
|
• modest dilation of the ventricles after tamoxifen treatment
|
|
• left ventricular end-diastolic and end-systolic volume in the cavity are increased and left ventricular ejection fraction is decreased
|
|
• about 5 weeks after tamoxifen treatment, mutant heart rate is significantly reduced
|
|
• about 6 weeks after tamoxifen treatment, 2 mutants showed abrupt onset of ventricular tachyarrhythmia followed by sudden death
|
|
• about 6 weeks after tamoxifen treatment, 2 mutants showed abrupt onset of ventricular tachyarrhythmia followed by sudden death
|
|
• tachyarrhythmia is initiated by premature ventricular depolarization
|
muscle
|
• after tamoxifen treatment enlarged hyperchromatic myocyte nuclei are seen
• after tamoxifen treatment intercalated disc structures and intercellular space are absent
• after tamoxifen treatment sarcomeres appear distorted and compressed with wider, less dense Z-lines
|
|
• after tamoxifen treatment intercalated disc structures are absent
|
|
• left ventricular end-diastolic and end-systolic volume in the cavity are increased and left ventricular ejection fraction is decreased
|
